He Needs An Expensive Drug. A Copay Card Helped — Until It Didn’t.

Over nan people of 2025, Jayant Mishra of Mission Viejo, California, progressively developed scaly, itchy reddish patches connected his skin. Then came nan symptom and swelling successful nan joints of his hands, making it difficult to do his activity astatine a bank.

His superior attraction expert referred him to a rheumatologist, who diagnosed psoriatic arthritis. She advised Mishra that while there's nary cure, location were galore caller medicines that could support nan autoimmune disease successful check, and she recommended one, Otezla.

At first, Mishra balked. He knew nan medicines were expensive. He worried astir broadside effects. He thought he could negociate pinch over-the-counter drugs.

But by September he was successful truthful overmuch symptom that he agreed to effort a starter battalion provided by Otezla's manufacturer, Amgen. It worked: The tegument lesions disappeared, and nan associated symptom that kept him up astatine nighttime dissipated. He was sold.

His rheumatologist sewage support for nan supplier from his insurer, UnitedHealthcare, and signed him up for Amgen's copayment assistance program. Having enrolled different patients, she told Mishra nan copay card, akin to a in installments card, should past a year, he said, shielding him from nan drug's precocious database price: astir $5,000 for a 30-day supply, according to GoodRx.

He said nan expert explained that, successful her patients' experience, insurers and their drugstore use managers negotiated a profoundly discounted value pinch Amgen — she estimated $1,400 to $2,200 a month. Patients paid a percent of that amount, their "patient responsibility," utilizing nan copay card.

Mishra said he was approved for a copay paper covering $9,450 a year. "I was happy erstwhile I sewage nan message," he said.

He added that nan expert reassured him astir nan cost. "She said: 'You shouldn't person to salary thing out-of-pocket. Your copay paper will screen this.'"

He started nan medicine and, astatine first, paid nothing.

Then nan measure came.

The aesculapian service

Otezla, which comes successful a pill, is approved to dainty immoderate autoimmune disorders, including psoriatic arthritis.

The bill

$441.02, for nan 2nd month's capable of nan supplier — earlier Mishra chose to ration alternatively than refill his prescription, because his copay paper was empty.

The security connection from UnitedHealthcare's drugstore use manager, Optum Rx — different subsidiary of nan aforesaid genitor company, UnitedHealth Group — showed it did not supply a negotiated discount and covered conscionable $308.34 of nan afloat $5,253.85 complaint for a 30-day supply. The charges for nan 2nd period depleted nan copay paper and near Mishra owing nan balance.

The billing problem: Copay paper 'tug-of-war'

Copay assistance programs are portion of a "tug-of-war betwixt supplier manufacturers and insurers," said Aaron Kesselheim, a professor of medicine astatine Harvard Medical School who studies nan pharmaceutical industry.

The worth of drugmakers' copay cards has go much unpredictable arsenic insurers effort to restrict their use. Many security plans, for instance, do not count nan money from a copay programme toward a patient's deductible.

And patients who usage a copay paper tin upwind up paying afloat aliases astir afloat value alternatively than nan discounted complaint negotiated by their insurer's drugstore use manager.

"When you purchased your medicine a Manufacturer Coupon was used," Mishra's mentation of benefits statements read, successful mini letters. The magnitude nan copay paper covered "was not applied towards your Deductible and Out of Pocket Maximum."

Caroline Landree, a spokesperson for UnitedHealthcare, said that "the copay paper is an statement betwixt nan diligent and nan pharmacy. It is utilized extracurricular of insurance."

In an emailed statement, Elissa Snook, a spokesperson for Amgen, expressed a different position of who was responsible for Mishra's dilemma: "Copay assistance programs are designed to thief patients commencement and enactment connected prescribed therapy, but nan worth of that assistance tin beryllium exhausted much quickly erstwhile a wellness scheme requires patients to salary nan afloat database value of a medicine."

Few patients tin spend nan database prices that pharmaceutical manufacturers complaint successful nan United States for brand-name drugs.

Insurers insulate themselves and their customers from those higher prices done drugstore use managers' negotiated discounts. They might, for example, designate definite narcotics arsenic preferred medications for scheme members successful speech for nan shaper agreeing to a important value reduction.

Manufacturers' copay assistance programs connection different measurement for patients to debar paying afloat price. The assistance is intended to promote patients to take an expensive, brand-name supplier — not 1 that "treats nan aforesaid information that nan insurer has gotten for a cheaper price," said Fiona Scott Morton, an economist astatine nan Yale School of Management who studies supplier pricing.

The assistance besides discourages patients from discussing pinch their expert whether a cheaper, generic supplier would do, supplier manufacture researchers said.

While nan Food and Drug Administration first approved a generic type of Otezla successful 2021, Amgen has sued to artifact U.S. income of its generic competitors, ensuring nan brand-name supplier has patent protection until 2028. Generic versions are disposable overseas and successful Canada, wherever patients tin acquisition it successful immoderate cases for little than $100 a month.

Mishra said 1 of his children joked he could screen a travel to sojourn relatives successful India simply by purchasing his medicine while he was there.

The resolution

Mishra has a wellness scheme pinch a $5,000 deductible and contributes to a tax-free wellness savings account.

In September, he paid for nan first month's proviso of Otezla pinch nan copay card. But paying for October's proviso emptied nan paper — which he primitively expected to past a twelvemonth — and he said he utilized his HSA to salary for nan astir $400 that remained.

But wary of what nan supplier would costs successful November and December, Mishra said, he tried to dispersed retired nan pills he had near from nan starter battalion and nan first 2 months' supply. He skipped immoderate days and took only half of nan prescribed dose to agelong nan proviso for 2 much months, knowing he would get a caller copay paper pinch nan caller year. Many of his symptoms returned, he said.

In January, he sewage different copay card, bully for $9,450, which again wasn't capable to salary for 2 months' supply. He again paid nan remaining equilibrium successful February from his HSA to count toward his $5,000 yearly deductible. This clip he owed $550, he said.

Mishra said his symptoms person resolved. With nary hint what he'd beryllium charged for March's supply, he called UnitedHealthcare successful precocious February and was told he would request to salary $4,450 for nan period to meet his out-of-pocket maximum, he said.

But he said he pressed nan typical further, asking why UnitedHealthcare doesn't person a negotiated price. It does, they told him. "Actual value is $6,995.36."

The takeaway

Copay cards and drugmaker programs that committedness patients "you could salary $0" activity successful mysterious ways.

On nan 1 hand, they promote patients to usage brand-name aliases costly narcotics that are disconnected insurers' formularies, aliases lists of preferred, covered drugs. On nan other, galore patients couldn't spend prescribed medicines without them.

Patients pinch nationalist insurance, specified arsenic Medicare and Medicaid, are not permitted to usage nan cards, because nan authorities considers them an extremity tally astir its attempts to bring down supplier spending.

Using a copay paper has gotten trickier arsenic insurers push back. First, patients request to understand whether location is an yearly dollar aliases clip limit connected nan paper and really it useful pinch their insurance. Otherwise, they consequence ending up reliant connected a supplier they can't afford.

Less costly narcotics often tin suffice. For example, location are a number of medicines to dainty psoriatic arthritis, immoderate of which whitethorn beryllium cheaper aliases person amended sum from a peculiar insurer. Patients should inquire their doctors whether cheaper medicines will work.

It besides tin thief patients to see their prescriptions erstwhile they prime a wellness plan. Landree, of UnitedHealthcare, said Mishra could person selected a scheme for 2026 that would person covered Otezla for a $100 copay each month, though that would person meant a higher premium.

"Personally I'm not successful financial distress — I tin spend it," Mishra said. "But it was sticker shock, and it conscionable doesn't look right."

Bill of nan Month is simply a crowdsourced investigation by KFF Health News and The Washington Post's Well+Being that dissects and explains aesculapian bills. Since 2018, this bid has helped galore patients and readers get their aesculapian bills reduced, and it has been cited successful statehouses, astatine nan U.S. Capitol, and astatine nan White House. Do you person a confusing aliases outrageous aesculapian measure you want to share? Tell america astir it!